XmAb 819 for advanced kidney cancer and other solid tumors
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests a new drug called XmAb 819 to treat advanced clear cell kidney cancer and other cancers that have grown despite standard treatments. It mainly looks at safety and how the body responds, with the goal of finding signs the drug can work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced cancer that has measurable tumors on scan (or in a previously radiated area, the cancer has proven to be progressing).
- Your cancer has progressed after standard treatments (or you have relapse and treatment-resistant disease).
- You feel well enough for treatment, with an ECOG score of 0 or 1 (roughly fully active or limited but able to do self-care).
- The study site can get usable tumor tissue for testing (slides or preserved biopsy block).
- You have not previously had an investigational treatment aimed at ENPP3/CD203c.
- You do not have certain health issues that would make treatment unsafe (like active brain/spinal cancer in the head area, serious drug allergy history, recent chemo, or uncontrolled autoimmune disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
This trial tests a new combination of targeted medicines (including 177Lu girentuximab) plus immunotherapy to treat people with advanced clear cell kidney cancer who have not had prior systemic (whole-body) treatment. It aims to shrink tumors and control disease by attacking cancer in multiple ways.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.